Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]

DRUG2 trials

Sponsors

Canadian Medical and Surgical Knowledge Translation Research Group, Ottawa Heart Institute Research Corporation

Conditions

Cardiovascular DiseasesCardiovascular Risk FactorCommunity Acquired Pneumonia (CAP)Diabetes Mellitus, Type 2InflammationInflammation Plaque, AtheroscleroticTriglycerides High

Phase 3

Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia

RecruitingNCT06710080

Ottawa Heart Institute Research CorporationCommunity Acquired Pneumonia (CAP), Inflammation, Inflammation Plaque, Atherosclerotic

Start: 2026-04-08End: 2027-06-01Target: 168Updated: 2026-05-11

Phase 4

The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk

CompletedNCT04562467

Canadian Medical and Surgical Knowledge Translation Research GroupCardiovascular Diseases, Cardiovascular Risk Factor, Diabetes Mellitus, Type 2 +1

Start: 2020-09-24End: 2023-05-25Updated: 2024-04-02

Related Papers

Targeting Vascular Inflammation In Patients with Community-Acquired Pneumonia (TIN-CAP): protocol for a multicentre, randomised, double-blind, placebo-controlled trial.

2026-03-04

Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.

2024-03-284 citations